Shareholder Information Session - Perth
Shareholder Information Session - Perth
Brisbane, June 4, 2019 AEST (ABN Newswire) - Anatara Lifesciences Ltd (ASX:ANR) is pleased to invite existing and potential shareholders to attend an information briefing session in Perth to discuss the Company's work in gastrointestinal health and to meet Chief Executive Officer (CEO), Steven Lydeamore.

Over a light lunch, Steve will discuss Anatara's progress in commercialising innovative, evidence-based products for areas of gastrointestinal health where there is significant unmet need. The Company's lead program is focused on the development of a dietary supplement to fill a gap in currently available treatment options for sufferers of gastrointestinal conditions such as Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS), which affects more than 20% of the Australian population.

Shareholder information session details are as follows:

Date: Tuesday 18th June 2019

Time: 12.30pm - 2.30pm Lunch will be provided

Venue: Australian Institute of Company Directors (AICD) Business Centre

Allendale Square, 1/77 St Georges Terrace, Perth, WA 6000

Please kindly register your attendance and any dietary requirements, by Wednesday 12th June 2019 to Hayley van der Meer at

About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit



General inquiries
Steven Lydeamore
Anatara Lifesciences
T: +61-438-027-172

Media inquiries:
Jane Lowe
Managing Director
IR Department
T: +61-411-117-774

Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 22) (Last 30 Days: 107) (Since Published: 2638)